TOKYO -- Japanese drugmaker Shionogi said Monday that preliminary laboratory studies suggest its COVID-19 tablet inhibits the severity of infections from the highly transmissible omicron variant, providing optimism that the low-cost treatment may help prevent a surge in hospitalizations.
Coronavirus
Shionogi's new COVID pill appears to ease omicron symptoms
Japanese drugmaker's treatment raises hopes of limiting hospitalizations
The Japanese pharmaceutical maker began clinical trails of its COVID treatment pill in September. (Photo courtesy of Shionogi)
Read Next
Latest on Coronavirus
